Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
PR Newswire
CAMBRIDGE, Mass.
,
Sept. 1, 2022
/PRNewswire/ —
Akebia Therapeutics, Inc.
(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that
John Butler
, Chief Executive Officer, will present virtually at the H.C. Wainwright 24
th
Annual Global Investment Conference. The hybrid conference will take place September 12–14, 2022.
The presentation will be available on-demand beginning
September 12, 2022
through the Investors section of Akebia’s website at
https://ir.akebia.com
for approximately 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Cambridge, Massachusetts
. For more information, please visit our website at
www.akebia.com
, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
[email protected]
View original content to download multimedia:
https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-virtually-at-the-hc-wainwright-24th-annual-global-investment-conference-301615782.html
SOURCE Akebia Therapeutics
Featured image: Megapixl © Visivasnc